IsoRay, Inc. (DE) (ISR): Price and Financial Metrics


IsoRay, Inc. (DE) (ISR): $0.30

0.01 (+2.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ISR POWR Grades


  • Value is the dimension where ISR ranks best; there it ranks ahead of 47.37% of US stocks.
  • ISR's strongest trending metric is Momentum; it's been moving down over the last 57 days.
  • ISR's current lowest rank is in the Quality metric (where it is better than 11.32% of US stocks).

ISR Stock Summary

  • ISR has a higher market value than only 9.07% of US stocks; more precisely, its current market capitalization is $50,992,455.
  • ISR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 6.07% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ISR comes in at -110.25% -- higher than that of only 3.4% of stocks in our set.
  • Stocks that are quantitatively similar to ISR, based on their financial statements, market capitalization, and price volatility, are REKR, OSIS, AXGN, CSII, and VAPO.
  • ISR's SEC filings can be seen here. And to visit Isoray Inc's official web site, go to www.isoray.com.

ISR Valuation Summary

  • ISR's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
  • Over the past 192 months, ISR's price/sales ratio has gone down 111.2.
  • Over the past 192 months, ISR's price/sales ratio has gone down 111.2.

Below are key valuation metrics over time for ISR.

Stock Date P/S P/B P/E EV/EBIT
ISR 2021-08-31 9.4 1.3 -25.7 -7.5
ISR 2021-08-30 9.3 1.3 -25.4 -7.2
ISR 2021-08-27 9.6 1.4 -26.1 -7.9
ISR 2021-08-26 9.8 1.4 -26.7 -8.5
ISR 2021-08-25 9.9 1.4 -27.1 -8.9
ISR 2021-08-24 9.4 1.3 -25.8 -7.6

ISR Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -75.03%.
  • The 4 year cash and equivalents growth rate now stands at -84.77%.
  • The 5 year revenue growth rate now stands at 86.88%.
ISR's revenue has moved up $941,000 over the prior 15 months.

The table below shows ISR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10.69 -5.136 -5.653
2021-09-30 10.233 -4.583 -4.917
2021-06-30 10.053 -2.837 -3.39
2021-03-31 9.622 -2.567 -3.52
2020-12-31 9.902 -2.808 -3.323
2020-09-30 9.749 -3.326 -3.354

ISR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ISR has a Quality Grade of D, ranking ahead of 9.41% of graded US stocks.
  • ISR's asset turnover comes in at 0.243 -- ranking 139th of 186 Medical Equipment stocks.
  • SIEN, LAKE, and NAOV are the stocks whose asset turnover ratios are most correlated with ISR.

The table below shows ISR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.243 0.509 -0.639
2021-03-31 0.372 0.504 -0.657
2020-12-31 0.961 0.524 -0.605
2020-09-30 1.126 0.527 -0.610
2020-06-30 1.055 0.529 -0.642
2020-03-31 0.996 0.529 -0.717

ISR Stock Price Chart Interactive Chart >

Price chart for ISR

ISR Price/Volume Stats

Current price $0.30 52-week high $0.94
Prev. close $0.29 52-week low $0.25
Day low $0.28 Volume 46,772
Day high $0.30 Avg. volume 403,461
50-day MA $0.33 Dividend yield N/A
200-day MA $0.46 Market Cap 42.56M

IsoRay, Inc. (DE) (ISR) Company Bio


Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.


ISR Latest News Stream


Event/Time News Detail
Loading, please wait...

ISR Latest Social Stream


Loading social stream, please wait...

View Full ISR Social Stream

Latest ISR News From Around the Web

Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.

Isoray, Inc. (ISR) CEO Lori Woods on Q2 2022 Results - Earnings Call Transcript

Isoray, Inc. (ISR) Q2 2022 Earnings Conference Call Feb 08, 2022, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Capital Kyle Krueger -...

SA Transcripts on Seeking Alpha | February 9, 2022

Isoray Announces Second Quarter Fiscal 2022 Financial Results

Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year

GlobeNewswire | February 8, 2022

IsoRay GAAP EPS of -$0.01 in-line, revenue of $2.82M beats by $0.02M

IsoRay press release (ISR): Q2 GAAP EPS of -$0.01 in-line.Revenue of $2.82M (+19.5% Y/Y) beats by $0.02M.Shares -0.39%.Gross profit as a percentage of revenues was 43.3% for the

Seeking Alpha | February 8, 2022

IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

IsoRay Q2 2022 Earnings Preview

IsoRay (NYSE:ISR) is scheduled to announce Q2 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $2.8M

Seeking Alpha | February 7, 2022

Read More 'ISR' Stories Here

ISR Price Returns

1-mo -3.32%
3-mo -15.04%
6-mo -38.78%
1-year -61.60%
3-year -33.51%
5-year -47.37%
YTD -22.64%
2021 -13.82%
2020 -27.93%
2019 108.13%
2018 -24.81%
2017 -31.21%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7309 seconds.